Skip to content

Study · Animal study (in vivo) · dog · 2005

2 results

Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.

Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP

Proceedings of the National Academy of Sciences of the United States of America18 Apr 2005Cited by 56 (Europe PMC)

PMID15837921 (opens in a new tab)PMCIDPMC1087916 (opens in a new tab)DOI10.1073/pnas.0409249102 (opens in a new tab)PepBankPUB-15837921
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In gene-treated hemophilia A dogs, DDAVP did not increase plasma cFVIII levels.

    In plain wordsIn dogs with gene-treated hemophilia A, DDAVP did not increase plasma cFVIII levels.

    Peptide
    Desmopressin
    Outcome
    No significant changePlasma cFVIII
    Study

    dogn: not reported in source

    Hemophilia A dogs treated with liver-directed neonatal gene therapy
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that DDAVP did not increase plasma cFVIII levels in the RV-treated dogs, although von Willebrand factor was increased appropriately.
    1 context sentence
    Summary · context
    Because the plasma cFVIII in these RV-treated dogs derives primarily from transduced hepatocytes, they provided a unique opportunity to study the biology of the DDAVP response.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In gene-treated hemophilia A dogs, DDAVP increased von Willebrand factor.

    In plain wordsIn dogs with gene-treated hemophilia A, DDAVP increased von Willebrand factor.

    Peptide
    Desmopressin
    Outcome
    IncreaseVon Willebrand factor
    Study

    dogn: not reported in source

    Hemophilia A dogs treated with liver-directed neonatal gene therapy
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that DDAVP did not increase plasma cFVIII levels in the RV-treated dogs, although von Willebrand factor was increased appropriately.
    1 context sentence
    Summary · context
    Because the plasma cFVIII in these RV-treated dogs derives primarily from transduced hepatocytes, they provided a unique opportunity to study the biology of the DDAVP response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.